Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Operating Expenses (2016 - 2025)

Collegium Pharmaceutical has reported Operating Expenses over the past 10 years, most recently at $67.6 million for Q4 2025.

  • Quarterly results put Operating Expenses at $67.6 million for Q4 2025, up 12.37% from a year ago — trailing twelve months through Dec 2025 was $283.6 million (up 36.72% YoY), and the annual figure for FY2025 was $283.6 million, up 36.72%.
  • Operating Expenses for Q4 2025 was $67.6 million at Collegium Pharmaceutical, up from $67.1 million in the prior quarter.
  • Over the last five years, Operating Expenses for COLL hit a ceiling of $75.6 million in Q1 2025 and a floor of $32.0 million in Q3 2021.
  • Median Operating Expenses over the past 5 years was $41.6 million (2022), compared with a mean of $48.0 million.
  • Peak annual rise in Operating Expenses hit 82.68% in 2024, while the deepest fall reached 20.45% in 2024.
  • Collegium Pharmaceutical's Operating Expenses stood at $32.8 million in 2021, then grew by 15.99% to $38.0 million in 2022, then decreased by 13.38% to $32.9 million in 2023, then soared by 82.68% to $60.2 million in 2024, then rose by 12.37% to $67.6 million in 2025.
  • The last three reported values for Operating Expenses were $67.6 million (Q4 2025), $67.1 million (Q3 2025), and $73.3 million (Q2 2025) per Business Quant data.